| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Second Regular National Report on the Implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
102379
Status
Published
Date of creation
2011-09-29 10:48 UTC (kadio_amidou@yahoo.fr)
Date of publication
2011-09-29 10:48 UTC (kadio_amidou@yahoo.fr)

This document is also available in the following languages:
Origin of report
Country
  • Chad
Contact officer for report
Coordinates
Point Focal National Biosécurité Amidou Kadiom
Chef de Division des Aires Protégées, Point Focal National Biosécurité
Direction des Parcs Nationaux, des Réserves de Faune et dela Chasse
BP 447 N'Djamena Tchad
N'Djamena
Chad
Phone:+235 66 49 58 41/+99 83 65 03
Email:kadio_amidou@yahoo.fr
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
FR
Environnement, Agriculture, Enseignement Supérieur, Mines et Énergies,  Santé, Justice,  Communication, Chambre de Commerce,  Direction Générale des Douanes, Assemblée Nationale et  Association des  Consommateurs         
Submission
10. Date of submission
2011-09-29
11. Time period covered by this report
Start date
2008-01-01
Time period covered by this report
End date
2011-09-29
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
  • A domestic regulatory framework is partially in place
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety regulations
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • Yes
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • Yes
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
  • Less than 5
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Yes
21. Here you may provide further details on the implementation of Article 2 in your country:
FR
L'article 10 du projet de loi prévoit:
Toute personne physique ou morale désirant exporter un OVM ou un produit dérivé à partir du territoire tchadien doit fournir à l'Autorité Nationale Compétente une autorisation préalable donnée en connaissance de cause délivrée par écrit par l'Autorité compétente du pays d'importation.
Aucune disposition de la présente Loi n'exonère l'exportateur du respect des règles du commerce international des produits agricoles en général, et de ceux issus de la biotechnologie moderne en particulier, tout au long de la procédure de délivrance de l'autorisation préalable en connaissance de cause.
Si un OVM ou un produit dérivé fait l'objet d'une interdiction légale sur le territoire national, son exportation ne peut en aucun cas être autorisée.
Article 5 – Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • No
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
  • No
26. Does your country regulate the contained use of LMOs?
  • No
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
  • No
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
  • Yes
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • No
34. Does your country have the capacity to detect and identify LMOs?
  • No
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • No
36. Has your country established legal requirements for the accuracy of information contained in the notification?
  • No
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
FR
l est prévu dans les articles 18 et 19 du projet de loi ce qui suit:               
Article 18 :
L'Autorité Nationale Compétente s'assure que l'importation dans le pays d'un OVM ou d'un produit dérivé d'OVM ne s'effectue qu'après qu'elle en ait donné l'autorisation par écrit.

L'Autorité Nationale Compétente évalue l'information présentée par l'auteur de la  notification ou celle disponible au Centre d'échange pour la prévention des risques biotechnologiques, selon le cas. Elle peut prendre l'une des décisions ci-après :
1) autoriser l'importation, avec ou sans condition, en tenant compte des résultats de l'évaluation des risques effectuée par les institutions compétentes, et en indiquant si cette décision s'appliquera ou pas aux importations ultérieures du même OVM;
2) interdire l'importation ;
3) demander des renseignements pertinents supplémentaires conformément à la présente Loi et à l'annexe I du Protocole de Cartagena;
4) informer l'auteur de la notification que la période spécifiée au présent alinéa est prolongée d'une durée définie.
Avant de prendre une décision, l'Autorité Nationale Compétente peut demander à l'auteur de la notification tous les éléments d'information complémentaires jugés nécessaires. Tout notifiant n'étant pas en mesure de fournir l'information demandée sera considéré comme ayant renoncé à sa requête.

Article 19 :
Si toutes les conditions sont réunies, l'Autorité Nationale Compétente signifie à l'auteur de la notification sa décision par écrit, avec copie au Centre d'échange pour la prévention des risques biotechnologiques dans un délai de cent quatre vingt (180) jours.

Toute autorisation spécifie les étapes successives de la mise en oeuvre de la procédure de décision et indique les risques qui doivent être évalués à chaque étape.

Cependant, si le Comité National Technique et Scientifique  considère qu'il n'y a pas de risques significatifs pour la santé humaine, animale et l'environnement ; l'Autorité Nationale Compétente peut se contenter d'une procédure simplifiée.
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
  • No
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • No
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
  • No
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
  • No
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
  • No
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
  • Yes
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
FR
L'article 17 du projet de loi dit ce qui suit:
Dans un délai n'excédant pas quatre vingt dix (90) jours de la réception de la demande ou de la notification, l'ANC (Autorité Nationale Compétente) adresse un accusé de réception à l'auteur de la demande d'autorisation ou de la notification. L'accusé de réception indique la date de réception de la demande ou de la notification, le fait qu'elle contienne ou non les mentions prévues par le texte précédent et la procédure de prise de décision. Il indique également les informations complémentaires exigées par l'ANC pour éclairer la prise de décision notamment :
• les conséquences d'une dissémination involontaire ;
• le rapport et la documentation d'évaluation des risques et le niveau de sécurité ainsi que les dispositions à prendre en cas d'urgence;
• le transfert précédent ou actuel dans un autre pays ;
• la description claire et séquentielle des étapes suivies lors de la mise en œuvre du projet et les procédures d'évaluation des risques effectuées à chaque étape ainsi que le mode d'élimination des déchets ;
• le lieu et le but pour lequel l'OVM  ou le produit dérivé d'OVM doit être élaboré, utilisé, conservé, disséminé ou commercialisé ainsi que les conditions d'utilisation ou d'emballage et les procédures d'étiquetage ;
• les informations sur le matériau qui se trouve au Centre d'échange pour la prévention des risques biotechnologiques si la demande préconise l'importation d'un OVM ou un produit dérivé d'OVM directement destiné à l'alimentation humaine ou animale ou à être transformé ;
• les plans d'urgence en cas de dissémination accidentelle ou de tout autre accident.
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • No
65. Has your country ever received a request for a review of a decision?
  • No
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
71. Here you may provide further details on the implementation of Article 12 in your country:
FR
Il est dit à l'article 18 du projet de loi que :
L'Autorité Nationale Compétente s'assure que l'importation dans le pays d'un OVM ou d'un produit dérivé d'OVM ne s'effectue qu'après qu'elle en ait donné l'autorisation par écrit.

Autorité Nationale Compétente évalue l'information présentée par l'auteur de la  notification ou celle disponible au Centre d'échange pour la prévention des risques biotechnologiques, selon le cas. Elle peut prendre l'une des décisions ci-après :
1) autoriser l'importation, avec ou sans condition, en tenant compte des résultats de l'évaluation des risques effectuée par les institutions compétentes, et en indiquant si cette décision s'appliquera ou pas aux importations ultérieures du même OVM;
2) interdire l'importation ;
3) demander des renseignements pertinents supplémentaires conformément à la présente Loi et à l'annexe I du Protocole de Cartagena;
4) informer l'auteur de la notification que la période spécifiée au présent alinéa est prolongée d'une durée définie.
Avant de prendre une décision, l'Autorité Nationale Compétente peut demander à l'auteur de la notification tous les éléments d'information complémentaires jugés nécessaires. Tout notifiant n'étant pas en mesure de fournir l'information demandée sera considéré comme ayant renoncé à sa requête.                              ]
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
73. Has your country ever applied the simplified procedure?
  • No
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
  • No
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
  • No
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
  • No
85. Has your country established a mechanism for training national experts to conduct risk assessments?
  • No
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
  • No
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
  • No
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
  • No
89. Has your country submitted summary reports of the risk assessments to the BCH?
  • No
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
  • None
91. Has your country ever required the exporter to conduct the risk assessment(s)?
  • No
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
  • No
Article 16 – Risk management
94. Has your country established and maintained appropriate and operational mechanisms, measures and strategies to regulate, manage and control risks identified in risk assessments for:
94.1) LMOs for intentional introduction into the environment?
  • No
94.2) LMOs intended for direct use as food or feed, or for processing?
  • No
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • No
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • No
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
  • No
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • No
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
  • No
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
107. Here you may provide further details on the implementation of Article 17 in your country:
FR
Dans le projet de loi il est prévu tout de même aux aricles 31, 32 et 33 ce qui suit:
Article 31:
Tout accident consécutif à la dissémination d'un OVM ou d'un produit dérivé donne lieu à la mise en œuvre du plan d'urgence communiqué à l'ANC par le bénéficiaire de l'autorisation.
Un rapport circonstancié relatif à l'accident doit être adressé à l'ANC en indiquant:
1) les circonstances de l'accident ;
2) l'identité de l'OVM et le cas échéant, l'identité et la quantité des produits dérivés qui en ont été libérés;
3) toute information qui permet d'évaluer les effets de l'accident sur la santé humaine, animale et  l'environnement ;
4) les mesures d'urgence prises ou qui doivent être prises.

Article 32:
En cas de dommages graves et irréversibles, l'absence de certitude scientifique absolue ne peut servir de prétexte pour remettre à plus tard l'adoption de mesures effectives visant à prévenir la dégradation de l'environnement, la santé humaine et animale. 

Article 33 :
Dès réception de l'annonce de l'accident, l'ANC s'assure que le public et les services concernés ont été correctement informés et que les dispositions ont été prises par chacun pour faire face à l'accident. L'ANC doit sensibiliser les intervenants sur les dangers potentiels de l'accident. 
De même, l'ANC se doit de tenir informer les institutions compétentes des pays touchés ou susceptibles de l'être. Elle doit également informer le Centre d'échanges pour la prévention des risques biotechnologiques.    
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • No
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
  • No
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
  • No
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • No
114. Has your country established procedures for the sampling and detection of LMOs?
  • No
115. Here you may provide further details on the implementation of Article 18 in your country:
FR
Tout de même l'article 34 du projet de loi prévoit ceci:
Tout OVM ou produit dérivé doit être clairement identifié et étiqueté. L'identification doit  mentionner les traits et les caractéristiques de l'OVM ou du produit dérivé avec des détails suffisants pour en assurer la traçabilité.

Tout OVM ou produit dérivé doit être emballé suivant les normes fixées par les conventions internationales et les usages. Dans tous les cas, la nature, l'identité et le pourcentage de l'OVM ou du produit dérivé devront être clairement déclinés ainsi que les réactions et les risques que celui-ci pourrait entraîner.                      ]
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
  • Yes
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
  • Yes
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
  • Yes, more than one
119. In case your country designated more than one competent national authority, has your country conveyed to the Secretariat the respective responsibilities of those authorities?
  • Yes
120. Has your country made available the required information referred in questions 116-119 to the BCH?
  • Yes, all information
121. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • No
122. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes
123. Here you may provide further details on the implementation of Article 19 in your country:
FR
Un correspondant national est nommé par arrêté ministériel et placé sous l'autorité du Directeur des Parcs nationaux, des Réserves de Faune et de la Chasse au Ministère de l'Environnement et des Ressources halieutiques
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124. Please provide an overview of the status of the information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
124.a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information not available
124.b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information not available
124.c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
124.d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
124.e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information not available
124.f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
124.g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
124.h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
124.i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information not available
124.j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information not available
124.k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
124.l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
124.m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
124.n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
124.o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
124.p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
124.q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information not available
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • Yes
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • Yes
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Yes, in some cases
128. Has your country experienced difficulties accessing or using the BCH?
  • No
130. Is the information submitted by your country to the BCH complete and up-to date?
  • No
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
  • No
133. Does your country allow the notifier to identify information that is to be treated as confidential?
  • No
134. Here you may provide further details on the implementation of Article 21 in your country:
FR
L'Article 35 du projet de loi dit tout de même :
L'Autorité Nationale Compétente ne communique au tiers aucune information à caractère confidentiel si le notifiant en exige la confidentialité par écrit.
Toutefois, L'ANC peut toujours décider de porter des informations à la connaissance du public, malgré leur caractère confidentiel dans l'intérêt général après consultation de la personne concernée.

Si pour quelque raison que ce soit le notifiant retire la notification, l'Autorité Nationale Compétente est tenue de respecter le caractère confidentiel de l'information fournie. 
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
136. If you answered Yes to question 135, how were these resources made available?
  • Multilateral channels
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
  • Yes
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
141. If you answered Yes to question 140, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 150.
  • Average
142. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Pilot Biosafety Enabling Activity
  • Development of national biosafety frameworks
  • Implementation of national biosafety frameworks
  • Building Capacity for Effective Participation in the BCH (Phase I)
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
  • Human resources capacity development and training
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
  • Yes
146. Does your country still have capacity-building needs?
  • Yes
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
148. Has your country developed a capacity-building strategy or action plan?
  • No
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
152. Has your country established a biosafety website?
  • No
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • No
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
  • No
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
  • No
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes, to a limited extent
158. If you answered Yes to question 157, has your country cooperated with other States and international bodies?
  • Yes
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • None
Article 24 – Non-Parties
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
162. Has your country ever imported LMOs from a non-Party?
  • No
163. Has your country ever exported LMOs to a non-Party?
  • No
166. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?
  • No
167. Here you may provide further details on the implementation of Article 24 in your country:
FR
Le Tchad est bel et bien Partie au Protocole de Cartagena donc a le devoir de contribuer de l'information au Centre d'échange pour la prévention des risques biotechnologiques                           ]
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
  • Never
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • No
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • No
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • No
180. Has your country initiated steps towards ratification, acceptance or approval of the Nagoya-Kuala Lumpur Supplementary Protocol?
  • Yes
181. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:
FR
Le Ministre des Affaires Étrangères a saisi le Ministre de l'Environnement et des Ressources Halieutiques de la question et celui-ci est à pied d'œuvre pour finaliser les documents se rapportant à l'application du Protocole supplémentaire de Nagoya-Kuala Lampour                          
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
  • No
183. If your country did not submit previous reports, indicate the main challenges that hindered the submission
  • Difficulty in compiling the information from various sectors
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
FR
Implication de l'administration publique et des parties prenantes dans les processus de mise en œuvre du protocole,
2) mettre des moyens conséquents à la disposition de l'autorité en charge de la question relative aux OVM,
3) Renforcer les capacités des cadres tchadiens à mieux maîtriser les outils de communication du portail central,
4) Instituer des rencontres régulières entre le Point Focal, les autorités locales élargies aux personnes ressources pour un échange d'information sur les OVM,
5) Créer un site web BCH - Tchad pour l'enregistrement des données de base du Tchad,
6) sensibiliser des hommes d'affaires tchadiens  (exportateurs et importateurs), les douaniers et la population sur l'importance des OVM,
7) encourager les travaux de recherche agronomique et génétique,
8) initier des rencontres d'échange d'expériences avec les autres pays sur les questions relatives aux OVM,
9) élaborer et adopter  les lois, règlements et lignes directives relatifs aux OVM.                          
Comments on reporting format
185. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.
FR
Il n y a pas de difficultés majeures pour remplir le rapport. Les questions sont clairement posées et passent en revue tous les articles du Protocole de Cartagena sur la prévention des risques biotechnologiques.